Amol Akhade: Advanced cell therapy for solid tumors – Where do we stand?

Amol Akhade posted the following on LinkedIn:

“I don’t know who should know this more – Oncologists, patients, or both? There’s a lot of buzz surrounding advanced cell therapy for solid tumors, particularly in lung cancer. However, as of now, there is zero concrete data available.

As of today, FDA approvals for solid tumors are limited:

• CAR-T therapy: Zero approvals
• TCR therapy: One approval for synovial sarcoma MAGE T cell therapy (not for any other sarcoma or subgroups)
• TILS therapy: Approved only for melanoma

Considering the current landscape, it’s crucial that these therapies are only pursued as part of clinical trials and not outside of them. Stay informed.”

Source: Amol Akhade/LinkedIn

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.